지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2021.11
- 수록면
- 867 - 877 (11page)
- DOI
- 10.5009/gnl20353
이용수
초록· 키워드
오류제보하기
Background/Aims: Although anti-tumor necrosis factor (TNF) agents have been widely used to treat ulcerative colitis (UC), the real-world incidence of suboptimal response to anti-TNF agents has not been thoroughly investigated, especially among Asians.
Methods: Using the Korean National Health Insurance database, we collected data on UC patients who initiated anti-TNF agents between July 1, 2014, and June 30, 2017. We assessed suboptimal responses, including anti-TNF discontinuation or dose escalation, switching to other biologics, augmentation with a non-biologic therapy, and the requirement for colectomy.
Results: A total of 1,268 patients were included as new anti-TNF users (infliximab 713, adalimumab 433, golimumab 122). The proportion of patients who experienced at least one suboptimal response within 1 year among all patients was 63.5%, including 59.1%, 69.5%, and 68.0% of patients treated with infliximab, adalimumab, and golimumab, respectively. The cumulative incidences of at least one suboptimal response over time were 41.5%, 63.7%, 80.5%, and 87.1% at 6, 12, 24, and 36 months, respectively. Cox proportional hazards modeling revealed that adalimumab was associated with a higher risk of at least one suboptimal response (hazard ratio [HR], 1.29; 95% confidence interval [CI], 1.13 to 1.48), dose escalation (HR, 4.35; 95% CI, 2.97 to 6.38) and discontinuation (HR, 1.25; 95% CI, 1.03 to 1.52) than infliximab. Golimumab was associated with a higher risk of switching to other biologics than infliximab (HR, 1.78; 95% CI, 1.21 to 2.60).
Conclusions: More than half of Korean UC patients had suboptimal responses to anti-TNF agents within 1 year. UC patients treated with infliximab might be less prone to suboptimal responses than those treated with adalimumab or golimumab.
목차
등록된 정보가 없습니다.
참고문헌 (33)
참고문헌 신청
Magro F / 2017 / Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1 : definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders / J Crohns Colitis 11:649~670
최창환 / 2017 / 궤양성 대장염 치료 가이드라인 개정판 / 대한소화기학회지 69(1):1~28
Wee Khoon Ng / 2016 / Changing epidemiological trends of inflammatory bowel disease in Asia / Intestinal research 14(2):111~119
Kaplan GG / 2017 / Understanding and preventing the global increase of inflammatory bowel disease / Gastroenterology 152:313~321
Kotze PG / 2020 / Progression of inflammatory bowel diseases throughout Latin America and the Caribbean : a systematic review / Clin Gastroenterol Hepatol 18:304~312
최창환 / 2017 / 궤양성 대장염 치료 가이드라인 개정판 / 대한소화기학회지 69(1):1~28
Wee Khoon Ng / 2016 / Changing epidemiological trends of inflammatory bowel disease in Asia / Intestinal research 14(2):111~119
Kaplan GG / 2017 / Understanding and preventing the global increase of inflammatory bowel disease / Gastroenterology 152:313~321
Kotze PG / 2020 / Progression of inflammatory bowel diseases throughout Latin America and the Caribbean : a systematic review / Clin Gastroenterol Hepatol 18:304~312
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study
Gut and Liver
2021 .09
-
Current and Emerging Biologics for Ulcerative Colitis
Gut and Liver
2015 .01
-
Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?
Gut and Liver
2022 .01
-
Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naive Patients with Ulcerative Colitis
Gut and Liver
2021 .01
-
Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
Gut and Liver
2021 .01
-
Similar Clinical Outcomes of Early and Late Anti-TNF Initiation for Ulcerative Colitis: A Nationwide Population-Based Study
Yonsei Medical Journal
2020 .01
-
Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis
Intestinal research
2021 .01
-
Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
Intestinal research
2023 .01
-
Efficacy of restarting anti-tumor necrosis factor α agents after surgery in patients with Crohn’s disease
Intestinal research
2018 .01
-
Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients
Journal of Korean Medical Science
2017 .01
-
Remission of diffuse ulcerative duodenitis in a patient with ulcerative colitis after infliximab therapy: a case study and review of the literature
Intestinal research
2019 .01
-
Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure
Gut and Liver
2024 .07
-
Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study
Yonsei Medical Journal
2020 .01
-
Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
Intestinal research
2022 .07
-
Temporal trend in the natural history of ulcerative colitis in a country with a low incidence of ulcerative colitis from 2000 through 2018
Intestinal research
2021 .01
-
Factors Contributing to the Preference of Korean Patients with Crohn’s Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)
Gut and Liver
2016 .01
-
Lesson from Real-World Experience: Optimal Treatment with Anti-Tumor Necrosis Factor for Ulcerative Colitis
Gut and Liver
2021 .11
-
Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study
Gut and Liver
2015 .01
-
체계적 문헌고찰 및 메타분석: 크론병 환자에서 Infliximab과 Adalimumab의 유효성 비교
보건의료기술평가
2021 .01
-
Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease
Gut and Liver
2021 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0